Why the study?
Diabetic cardiomyopathy lacks effective treatments and its progression is not prevented by glycemic control, making the identification of new intervention targets like SIRT3 a critical research focus.
Does targeting SIRT3 ameliorate diabetic cardiomyopathy?
Does targeting SIRT3 ameliorate diabetic cardiomyopathy?
SIRT3 is a promising therapeutic target for the treatment and delay of diabetic cardiomyopathy.
SIRT3 modulation may improve diabetic cardiomyopathy; leaves open need for clinical trials to confirm benefit.
Diabetes mellitus (DM) is one of the most common chronic diseases worldwide, and diabetic cardiomyopathy (DCM) is one of the cardiovascular complications of DM, described as the development of abnormalities of myocardial structure/function associated with DM in the absence of coronary artery disease, hypertension, and valvular disease. The disease has an insidious onset and lacks effective treatment. Studies have shown that even with effective glycemic control, the progression of DCM cannot be prevented. Exploring the pathogenesis of DCM and identifying effective intervention targets is the focus and hotspot of current research. Silent message regulator 3 (Sirtuin3, SIRT3) is one of the members of the nicotinamide adenine dinucleotide (NAD + )‐dependent deacetylase family of sirtuins, and studies have confirmed that SIRT3 has a protective effect on cardiovascular disease and may become a new target for the treatment of cardiovascular diseases. Therefore, this paper emphasizes the role of SIRT3 in DCM, describes the mechanism of SIRT3 in DCM, and summarizes the methods to improve DCM by elevating the level of SIRT3, aiming to provide new perspectives for treating and delaying DCM.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: